Cadrenal Therapeutics, Inc. (CVKD): Total Liabilities
$1.59M
As of 2025-12-31
$1.50M
As of 2026-06-30
-36.9%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.59M | -40.8% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $2.68M | +224.6% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $826.9K | -86.9% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $6.33M | n/a | 2024-03-11, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cadrenal Therapeutics, Inc. (CVKD) | 2025-12-31 | $1.59M | -40.8% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $1.57M | +30.1% |
| Pulmatrix, Inc. (PULM) | 2025-12-31 | $329.0K | -67.0% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.58M | -4.7% |
| Bio-Path Holdings, Inc. (BPTH) | 2024-12-31 | $3.73M | +34.2% |
| Azitra, Inc. (AZTR) | 2025-12-31 | $1.22M | -26.3% |
| Protagenic Therapeutics, Inc.\new (PTIX) | 2026-03-31 | $1.03M | -79.5% |
| Petros Pharmaceuticals, Inc. (PTPI) | 2025-12-31 | $2.29M | -87.3% |
| Polaryx Therapeutics, Inc. (PLYX) | 2025-12-31 | $605.0K | +109.3% |
Compare CVKD, LEXX, PULM, ISCO side by side · Screen every company in Pharmaceutical Preparations ↗